Cerapedics Announces Vizient Supplier Agreement for PearlMatrix® P-15 Peptide-Enhanced Bone Graft for Lumbar Spine Fusion
Cerapedics, Inc. announced April 24 a supplier agreement with Vizient for PearlMatrix® P-15 Peptide Enhanced Bone Graft, a Class III drug-device combination product for adult patients with degenerative disc disease in the lumbar spine. The deal extends access to Vizient's network of academic medical centers, community hospitals, and integrated health delivery networks. PearlMatrix uses a 15-amino-acid peptide (a fragment of Type I collagen) bound to anorganic bone mineral as a bone growth accelerator — one of the few peptide-enhanced devices on the U.S. orthopedics market.